Completed PHASE3 INTERVENTIONAL NCT00079508

Angiomax in Patients With HIT/HITTS Type II Undergoing CPB (HIT/TS)

A Phase III Study of Angiomax (Bivalirudin) in Patients With HIT/HITTS Type II Undergoing Cardiac Surgery on Cardiopulmonary Bypass (CPB)

Sponsor: The Medicines Company

Conditions Cardiovascular Disease Coronary Artery Bypass Surgery

Interventions Angiomax (bivalirudin)

Updated 6 times since 2017 Last updated: Nov 8, 2011 Started: Apr 30, 2004 Primary completion: Oct 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00079508, this PHASE3 trial focuses on Cardiovascular Disease and Coronary Artery Bypass Surgery and remains completed. Sponsored by The Medicines Company, it has been updated 6 times since 2004, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Apr 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

The Medicines Company

Data source: The Medicines Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cleveland, United States